CNS Therapeutics Privately held U.S. biopharma focused on novel CNS therapies with scheduled launches for Alzheimer’s Agitation, Traumatic Brain Injury, and PTSD, signaling potential for strategic partnerships, clinical research collaborations, and specialty distribution opportunities in neurology and care settings.

Small Team, Niche Focus Lean organization with 2-10 employees and a specialized pipeline, suggesting high-touch business development efforts, potential for channel partners and contract manufacturing or CRO collaborations to scale clinical and regulatory activities.

Wellness Synergy Historical linkage to Mandara CBD wellness products and-co-branding opportunities point to cross-sell potential with wellness retailers, integrative health clinics, and lifestyle brands seeking CNS support or post-treatment recovery products.

Funding & Revenue Current revenue in the low multimillion range with $2M funding; opportunities exist for strategic investment, grant collaborations, or joint ventures to accelerate development timelines and expand go-to-market functions.

Competitive Positioning Compared to larger CBD-focused peers, Mandara Biopharma occupies a boutique, research-driven niche in CNS disorders, offering a pathway for specialty distributors, academic partnerships, and conference-focused outreach to clinicians and patient advocacy groups.